Clinical Trials

Phase 1 Active not recruiting

29 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04079179 2025-09-18

NACHO-COBI

Phase 2 Recruiting

90 enrolled

MyeloidSarcoma

Histiocytosis, Langerhans-Cell, Xanthogranuloma, Juvenile, Histiocytosis, Sinus, Histiocytic Disorders, Malignant, Erdheim-Chester Disease, Histiocytic Sarcoma

NCT05441514 2025-09-16

Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

3 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

300 enrolled

Tumor-Agnostic

Neoplasms

NCT03108131 2025-05-28

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

49 enrolled 10 charts

Adenocarcinoma, Mucinous, Neoplasm Metastasis, Neoplasms

NCT02902029 2025-04-09

ImmunoCobiVem

186 enrolled

Melanoma

NCT04722575 2025-03-13

NEO-TIM

95 enrolled

Melanoma

NCT03224767 2025-02-18

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Phase 2 Not yet recruiting

24 enrolled

CNS

Craniopharyngioma

NCT06813079 2025-02-18

Using Tumor Models to Determine Treatments

25 enrolled

Gastrointestinal

Carcinoma, Carcinoma, Pancreatic Ductal

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

72 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04214418 2024-12-18

MEKiAUTO

Phase 1/2 Terminated

27 enrolled 12 charts

Gastrointestinal

Gastrointestinal Neoplasms

NCT04185831 2024-08-22

MEGALiT

167 enrolled

Other solid neoplasm

Solid Tumor

NCT03101254 2024-07-17

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Phase 1/2 Completed

5 enrolled 10 charts

Other hematologic neoplasm

Melanoma

NCT05159245 2024-07-15

FINPROVE

Phase 2 Recruiting

250 enrolled

Hematologic Neoplasms

NCT03395899 2024-06-18

ECLIPSE

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

71 enrolled

Breast

Breast Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Phase 2 Terminated

10 enrolled 10 charts

Melanoma

NCT02427893 2016-11-15

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Phase 3 Withdrawn